BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24914839)

  • 1. Prevalence of prostate cancer across the globe: what can autopsy studies teach us about this peculiar disease?
    Zlotta AR; Kuk C
    Arch Esp Urol; 2014 Jun; 67(5):400-8. PubMed ID: 24914839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.
    Zlotta AR; Egawa S; Pushkar D; Govorov A; Kimura T; Kido M; Takahashi H; Kuk C; Kovylina M; Aldaoud N; Fleshner N; Finelli A; Klotz L; Sykes J; Lockwood G; van der Kwast TH
    J Natl Cancer Inst; 2013 Jul; 105(14):1050-8. PubMed ID: 23847245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "More men die with prostate cancer than because of it" - an old adage that still holds true in the 21st century.
    C J; Y P; Sf B; Rj B
    Cancer Treat Res Commun; 2021; 26():100225. PubMed ID: 33360667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men.
    Zlotta AR; Egawa S; Pushkar D; Govorov A; Kimura T; Kido M; Takahashi H; Kuk C; Kovylina M; Aldaoud N; Fleshner N; Finelli A; Klotz L; Lockwood G; Sykes J; Kwast Tv
    Eur Urol; 2014 Oct; 66(4):619-22. PubMed ID: 25012523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study.
    Soos G; Tsakiris I; Szanto J; Turzo C; Haas PG; Dezso B
    Eur Urol; 2005 Nov; 48(5):739-44. PubMed ID: 16203079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
    Konety BR; Bird VY; Deorah S; Dahmoush L
    J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
    Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
    Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    Inaba H; Kimura T; Onuma H; Sato S; Kido M; Yamamoto T; Fukuda Y; Takahashi H; Egawa S
    J Urol; 2020 Aug; 204(2):267-272. PubMed ID: 32068492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent prostate cancer in Japanese men who die unnatural deaths: A forensic autopsy study.
    Kido M; Hitosugi M; Ishii K; Kamimura S; Joh K
    Prostate; 2015 Jun; 75(9):917-22. PubMed ID: 25728717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The frequency of latent prostatic carcinoma in young males: the Japanese experience.
    Shiraishi T; Watanabe M; Matsuura H; Kusano I; Yatani R; Stemmermann GN
    In Vivo; 1994; 8(3):445-7. PubMed ID: 7803732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No change in the prevalence of latent prostate cancer over the last 10 years: a forensic autopsy study in Japan.
    Hitosugi M; Mukaisho K; Kido M; Kamimura S; Furukawa S; Sugihara H
    Biomed Res; 2017; 38(5):307-312. PubMed ID: 29070780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series.
    Siadat F; Sykes J; Zlotta AR; Aldaoud N; Egawa S; Pushkar D; Kuk C; Bristow RG; Montironi R; van der Kwast T
    Prostate; 2015 Sep; 75(12):1277-84. PubMed ID: 25963383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
    Dall'Era MA; deVere-White R; Rodriguez D; Cress R
    Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
    Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher body mass index increases the risk for biopsy-mediated detection of prostate cancer in Chinese men.
    Hu MB; Bai PD; Wu YS; Zhang LM; Xu H; Na R; Jiang HW; Ding Q
    PLoS One; 2015; 10(4):e0124668. PubMed ID: 25861033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
    Tabei T; Taguri M; Sakai N; Koh H; Yosida M; Fujikawa A; Nirei T; Tsutsumi S; Ito H; Furuhata S; Kawahara T; Miyoshi Y; Noguchi S; Uemura H; Kobayashi K
    Prostate; 2020 Aug; 80(11):824-830. PubMed ID: 32433780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of prostate-specific antigen among Japanese-American and native Japanese men.
    Shibata A; Whittemore AS; Imai K; Kolonel LN; Wu AH; John EM; Stamey TA; Paffenbarger RS
    J Natl Cancer Inst; 1997 Nov; 89(22):1716-20. PubMed ID: 9390541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery.
    Revelo MP; Cookson MS; Chang SS; Shook MF; Smith JA; Shappell SB
    J Urol; 2004 Feb; 171(2 Pt 1):646-51. PubMed ID: 14713778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevelance of prostate cancer among Turkish men with prostate-specific antigen level of ≤100 ng/ml.
    Çalışkan S
    J Cancer Res Ther; 2018; 14(6):1256-1259. PubMed ID: 30488840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.